Price History
Sun Pharma is showing promising signs of growth, with higher price levels and a steady trend that places it in the accumulation zone. The 50-day and 200-day moving averages, both pointing upwards, suggest a positive momentum for the company, while increased delivery percentages underscore this optimistic outlook.
Sun Pharma reports a 3% year-over-year increase in EBITDA, anticipating high single-digit revenue growth for the fiscal year 2027, with R&D expenses accounting for 6-7% of sales. LG India has achieved an 8% year-over-year revenue growth and aims for mid-teen growth in fiscal year 2027, along with a target of double-digit EBITDA margin.
For investors seeking potential opportunities on May 25th, consider exploring LG Electronics, Eicher Motors, Sun Pharma, NTPC, and GAIL. These companies have been identified as top picks for the day.
According to Goldman Sachs, Sun Pharma experienced a 13% increase in quarterly sales year-over-year, along with a 6% boost in EBITDA. However, Goldman Sachs has not assigned a rating for Sun Pharma's stock as per the latest report.
Sun Pharma has announced it won't provide margin guidance due to potential disruptions from the ongoing conflict in West Asia. The pharmaceutical giant also expressed concern over increasing logistics and shipping expenses, casting doubt on their short-term profitability.
Sun Pharma's fourth-quarter revenue increased by 12.8%, in line with forecasts, prompting Morgan Stanley to maintain its positive stance on the company, keeping an Overweight rating.
Sun Pharma anticipates a robust, single-digit increase in revenue for the fiscal year 2027, driven by steady market conditions. The company plans to invest 6-7% of its sales into R&D and expects an effective tax rate of 25%.
Motilal Oswal maintains a bullish stance on Sun Pharma, predicting a potential increase of 15% to reach Rs 2,120. However, the company faces near-term hurdles such as rising marketing costs and erosion in US generic prices. Despite these challenges, Motilal Oswal anticipates a long-term growth rate of 12% for Sun Pharma.
Sun Pharmaceutical Industries (SUNPHARMA) demonstrates a consistent EPS growth of 11% annually over the past three years, driven by a corresponding 11% revenue increase. The company's insiders maintain a significant 12% stake worth ₹532B, indicating a strong alignment with shareholders and enhancing investor trust.
Analysts anticipate potential gains of up to 25% in Sun Pharma, Zydus Lifesciences, and Aurobindo Pharma. Investors may consider these stocks after evaluating the suggested 'BUY' recommendations and target prices for informed decision-making.
Sun Pharma's Q4 performance has earned three analyst recommendations of "Buy", reflecting optimism among investors. Yet, one analyst remains cautious, suggesting differing perspectives in the market.
Sun Pharma is pursuing growth in its specialty drug segment, aiming to overcome international obstacles and expand its offerings in the pharmaceutical industry.
Sun Pharma's U.S. revenue saw a slight dip of 0.9% in FY26, reaching $1.904 billion compared to $1.921 billion last year. The decline is primarily due to weakness in the generic drugs segment, despite an increase in sales for innovative medicines.
Sun Pharma has released their Q4 financial results, with specifics available now on ET NOW. Investors are encouraged to stay updated for further analysis of these earnings.
Sun Pharma expects a potential deceleration in their FY27 growth, attributable to complexities arising from regulatory obstacles and broader economic issues.
Sun Pharma's Q4 results show a significant increase in US formulation sales, while global markets remain steady across emerging and non-emerging regions. This positive trend in the US indicates promising growth for the pharmaceutical company.
Sun Pharma's shares experience a dip following the Q4 earnings miss, with US sales totaling $459 million.
Sun Pharma's Q4 profit fell short of expectations, coming in at INR 2,714 crore. Notably, the company announced a significant 500% dividend for its shareholders.
Sun Pharma's U.S. formulation sales have experienced a 1.1% year-on-year decline, reaching $459 million in the recent report.
Today, Sun Pharma, Hindalco, Eicher Motors, Torrent Pharma, and NTPC Green are set to release their Q4 results, with ITC, LIC, GAIL, Emami, Max Health, JSW Cement, Va Tech, and 3M India also under the spotlight for their financial performances. Investors will closely monitor these companies' results to gauge their performance in the recent quarter.
Sun Pharma's Q2 performance emphasizes growth in revenue, improved margins, and solid profits. The company's US income and Research & Development investments are crucial areas to watch moving forward.
Bernstein has recommended investing in Zydus, Lupin, and Sun Pharma, predicting a potential $75 billion growth in India's biopharmaceutical sector over the next decade. The firm believes that innovation, AI integration, and focus on niche therapies could propel this growth, with Zydus being their top choice. Biocon and Mankind Pharma were rated as less promising investments.
Sun Pharma conducted a large block deal, trading 214,109 shares for approximately INR 40 crore at a price of INR 1,867.7 per share.
Sun Pharma is projected to experience a significant 28% increase in quarterly profits, largely due to robust global specialty sales. The company's Q4 earnings are expected to reflect this positive trend.
Sun Pharma expects growth in Q4 to be driven by Unloxcyt and specialized drugs. Will this lead to another successful quarter? Let's see if they deliver on expectations. [The Economic Times]
In 2023, the Indian IPO market could set new records with listings from Jio Platforms and NSE, despite foreign investment outflows and currency pressure. The $11.8B Organon deal by Sun Pharma shows Indian companies' growing global acquisition power, yet energy costs and geopolitical risks remain significant challenges for the market. (Business Standard)
Sun Pharma is currently under investigation by CDSCO regarding their cosmetic injectables, which has sparked worries about adherence to regulations, approval procedures, and product supervision.
Pharmaceutical companies IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma, Wockhardt, Lupin, Divi's, Zydus, Torrent, JB Chem, Glenmark, and Ajanta have surged to their highest levels in the past year. Other notable gains were seen among stocks like these.
Sohum Asset's Chief Investment Officer anticipates a minor market correction (3-5%), suggesting that this could be an opportunity to invest in high-quality stocks. The firm is now primarily investing in large-cap companies such as Reliance, Maruti, Bajaj Finance, and Sun Pharma for enhanced stability.
On May 19, 2026, several stocks including BSE, Infosys, ICICI Bank, Sun Pharma, and Coforge receive buy recommendations due to positive sectoral trends. The suggested target prices are: BSE - Rs 4,283, Infosys - Rs 1,177, Sun Pharma - Rs 1,950, ICICI Bank - Rs 1,280, and Coforge - Rs 1,390. Investors are advised to set stop losses.
Sun Pharma shares reached a new 52-week high, breaking through the resistance of their recent downward trend. This potential buying opportunity might be worth considering for short-term traders.
Sun Pharma has announced a $12 billion acquisition of Organon, broadening its global product range significantly with additions focusing on women's health, biosimilars, and a strong market presence in China.
Sun Pharma has withdrawn its Doxorubicin Hydrochloride Liposome injection from the U.S. market due to the presence of glass particles, potentially posing a risk to patients undergoing cancer treatment. The company is working diligently to address this issue and ensure product safety.
Sun Pharma is set to review its Q4 and full-year 2026 financial results on May 22, 2026. The board will also discuss a potential final dividend for the year. The trading window will remain closed until May 24 in anticipation of this announcement.
Sun Pharma's stock soared 16% in 10 days, approaching its record high of ₹1,960.2, due to the $11.75B Organon acquisition deal. This significant purchase will enhance Sun Pharma's global reach, double its revenue to $12.4B, and fortify its focus areas in women's health and biosimilars.
Crisil and ICRA have maintained Sun Pharma's ratings despite acquisition news, but Crisil has placed its long-term rating under review. Both agencies upheld their assessment of Sun Pharma following the acquisition announcement.
Indian pharmaceutical giant Sun Pharma spearheads a projected $20.5 billion investment in the US market by 2026, signaling an expanding influence of Indian firms as key investors and collaborators within the American healthcare sector.
The pharmaceutical index Nifty Pharma reached a 52-week peak today at 24,033.45, registering a 2% increase. Notably, Wockhardt saw a 15% surge. Other companies like Lupin, Laurus, and Sun Pharma also hit new highs. Ajanta Pharma is experiencing strong growth in its branded business segment.